Bio Pharma Dive
MAY 22, 2025
Still, the therapies’ modest benefit as a maintenance therapy points to how better treatments are needed for small cell lung cancer, according to one physician.
Pharmaceutical Technology
MAY 22, 2025
Sanofi has agreed to acquire Vigil Neuroscience in a $470m deal, nearly a year after investing an initial $40m in the company.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Bio Pharma Dive
MAY 22, 2025
An eight-member panel voted unanimously against wider use of Pfizer’s Talzenna in advanced prostate cancer. Elsewhere, U.K. regulators cleared Sarepta to restart an Elevidys study and Altos Labs bought a startup.
pharmaphorum
MAY 22, 2025
The FDA has instructed Pfizer and Moderna to add stronger warnings to the labels of their COVID-19 vaccines about the risk of cardiotoxicity
Speaker: Brian Richardson, Brian Richardson, Founder and CEO of Richardson Consulting Group
Let’s face it—most ethics and compliance training programs aren’t winning awards for engagement. But that doesn’t mean they can’t be effective, captivating, and maybe even enjoyable! Join learning design expert Brian Richardson for a dynamic session on how to breathe new life into your ethics and compliance training. We'll explore innovative strategies to bring traditionally dry topics to life, making them resonate with learners and drive tangible change.
Bio Pharma Dive
MAY 22, 2025
Tumors with low- and ultra-low levels of a protein called HER2 are treatable with Enhertu, but harder to identify. New research shows AI can improve diagnosis.
Pharmaceutical Technology
MAY 22, 2025
UK biopharmaceutical companies saw a surge in venture financing for innovator drugs in 2024, with double the total deal value from 2022: $827m in 2022 to $1.7bn in 2024.
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
Pharmaceutical Technology
MAY 22, 2025
The lower out-of-pocket costs come at a time of governmental scrutiny on prescription drug prices in the US.
Bio Pharma Dive
MAY 22, 2025
Already a Vigil Neuroscience investor, Sanofi has agreed to buy the rest of the biotech’s shares for $8 apiece, representing a total deal value of $470 million.
Pharmaceutical Technology
MAY 22, 2025
Eli Lilly and Company has received marketing authorisation from the Australian Therapeutic Goods Administration (TGA) for Kisunla.
Bio Pharma Dive
MAY 22, 2025
The Danish drugmaker unveiled a series of initiatives to increase access to Wegovy and clamp down on use of the knock-off versions that have dented its sales forecasts.
Advertisement
Enhancing Transparency & Efficiency Throughout the Trial Lifecycle for AI Readiness
Pharmaceutical Technology
MAY 22, 2025
Orionis Biosciences has announced a multi-year partnership with Roches Genentech for small-molecule monovalent glue medicine.
XTalks
MAY 22, 2025
Observed each year on May 24, World Schizophrenia Awareness Day shines a light on one of the most misunderstood mental health conditions. Schizophrenia is a chronic psychiatric disorder that alters how individuals perceive reality, think and relate to others. Symptoms are typically categorized as positive (hallucinations, delusions), negative (emotional withdrawal, social disconnection) or cognitive (memory or attention deficits).
Pharmaceutical Technology
MAY 22, 2025
Paratek Pharmaceuticals has completed the acquisition of Optinose, valued at almost $330m, broadening its commercial product offerings.
pharmaphorum
MAY 22, 2025
Sanofi bids to add a drug candidate for Alzheimer's disease to its neurology pipeline via the acquisition of US biotech Vigil Neuroscience
Speaker: Amie Phillips Pablo, VP, Corporate Compliance & Privacy Officer at Novo Nordisk
In today’s complex healthcare environment, navigating third-party relationships has become even more challenging—whether it’s vendor relationships, employee activities, or patient-facing interactions. Left unmanaged, these conflicts can compromise trust, regulatory compliance, and even organizational reputation. So, how can healthcare teams stay ahead?
Pharma Times
MAY 22, 2025
Strategic collaboration aims to improve early diagnosis
pharmaphorum
MAY 22, 2025
There was good news for Johnson & Johnson at this week's ODAC meetings, but not for Roche, UroGen, and Pfizer
Pharma Times
MAY 22, 2025
The Board of the Medicines and Healthcare products Regulatory Agency (MHRA) has met in Scotland for the first time, marking a significant step in the agencys approach to delivering health and innovation priorities across the UK.
pharmaphorum
MAY 22, 2025
AstraZeneca has turned to another digital health partner to support its aspirations in chronic kidney disease (CKD)
Advertisement
Download this comprehensive guide to AI and ML in the R&D Laboratory Setting.
XTalks
MAY 22, 2025
On May 20, 2025, Kettering Health experienced a system-wide technology outage caused by a ransomware attack , disrupting services across its 14 medical centers in Ohio. The incident led to the cancellation of elective inpatient and outpatient procedures, disabled the systems call center and interrupted access to patient portals such as MyChart. Emergency rooms and outpatient clinics remain open.
pharmaphorum
MAY 22, 2025
Some patients in England living with severe haemophilia B will soon be able to do away with need for regular infusions
Pharmaceutical Commerce
MAY 22, 2025
In a Q&A with Pharma Commerce, Kurt Lunkwitz, ProRx Pharmas COO, uncovers the stringent requirements that 503B outsourcing facilities must abide by under the Drug Quality and Security Act, while also shedding light on the FDAs impact when it comes to improving the safety, quality, and trust in compounded drugs.
Drug Patent Watch
MAY 22, 2025
"Game-Changer for Life Sciences: DrugPatentWatch Now on Snowflake Marketplace The wait is over for life sciences professionals seeking to revolutionize their data management and analytics capabilities. We're thrilled to announce that DrugPatentWatch is now available on the Snowflake Marketplace, empowering users to unlock the full potential of their data and drive informed decision-making.
Speaker: Simran Kaur, Co-founder & CEO at Tattva.Health
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
Pharma Marketing Network
MAY 22, 2025
For decades, pharmaceutical marketing has relied on traditional playbookssegmentation models, field rep cadence, and linear messaging. But in 2025, the AI is Changing Pharma Marketing. Artificial intelligence (AI) is no longer a pilot initiative or innovation buzzword; its a competitive imperative. If youre wondering how brands like Eliquis , Rybelsus , or Dupixent are reaching HCPs and patients more efficiently, the answer often lies in how well theyre using AI.
XTalks
MAY 22, 2025
In this episode, Ayesha speaks with Ebrahim S. Delpassand, MD, Founder and CEO of RadioMedix , a company developing innovative radiopharmaceuticals for cancer diagnosis, monitoring and treatment. With a focus on both PET imaging and therapeutic radiopharmaceuticals labeled with alpha and beta emitters, RadioMedix is helping to shape the future of precision oncology.
Drug Patent Watch
MAY 22, 2025
"The Prescription Price Pinch: How 'March-In' Rights Could Revolutionize Your Medication Costs As the cost of prescription medications continues to skyrocket, a little-known provision in US law may hold the key to affordable healthcare for millions. 'March-In' rights, a provision of the Bayh-Dole Act, allows the government to step in and license patented technologies at a lower cost when they're deemed essential for public health.
XTalks
MAY 22, 2025
Diabetes affects hundreds of millions worldwide currently, about 537 million people live with the condition, with projections reaching nearly 643 million by 2030. These figures underline the urgency for novel and more effective treatment strategies, particularly for type 1 diabetes (T1D). Although T1D accounts for only about 5% to 10% of all diabetes cases , its onset at a young age and the need for lifelong management present unique challenges.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
pharmaphorum
MAY 22, 2025
This article Part 1 of a two-part series is a call to rethink biopharma strategy from the ground up. Well explore why legacy approaches fail, unpack how megatrends are rewriting the rules, and challenge leaders to rethink how we position, choose, execute, and govern in an exponential world.
Velocity Clinical Research
MAY 22, 2025
Henrik Watz, MD, PhD, presented compelling real-world data at the American Thoracic Society Annual Meeting on the long-term impact of dupilumab therapy in patients with severe asthma. Participants in the ProVENT study experienced sustained improvements in lung function, asthma control, and quality of life. Notably, more than half achieved asthma remission within two years of treatment.
Pharmaceutical Commerce
MAY 22, 2025
In the fourth part of his Pharma Commerce video interview, Kevin Dondarski, Deloittes life sciences R&D strategy leader, explains how GLP-1 therapies success can influence future investment strategies in high unmet need areas.
Drug Discovery World podcast
MAY 22, 2025
In the In Conversation With series, a part of the free DDW podcast, DDW speaks with members of the drug discovery industry about their work and how it helps turn science into business. In this episode, Megan Thomas is in conversation withPhil L’Huillier, CEO of Scancell. Following the companys recent partnership with the NHS Cancer Vaccine Launch Pad, enabling fast-tracked access for melanoma patients, we discuss how Scancell is addressing the scientific, clinical, and logistical challe
Expert insights. Personalized for you.
272 
Let's personalize your content